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Summary 27 
The Thai trial (RV144) indicates that a prime/boost vaccine combination that induces 28 
both T-cell and antibody responses may be desirable for an effective HIV vaccine. We 29 
have previously shown that immunisation with synthetic long peptides (SLP), 30 
covering the conserved parts of SIV, induced strong CD4 T-cell and antibody 31 
responses, but only modest CD8 T-cell responses. To generate a more balanced 32 
CD4/CD8 T-cell and antibody response, this study evaluated a pox-vector prime/SLP 33 
boost strategy in rhesus macaques. Priming with a replication competent NYVAC, 34 
encoding HIV-1 clade C gag, pol, nef, induced modest IFNγ T-cell immune 35 
responses, predominantly directed against HIV-1 gag. Booster immunization with 36 
SLP, covering the conserved parts of HIV-1 gag, pol, env, resulted in a more than 10 37 
fold increase in IFNγ ELISpot responses in 4 of 6 animals, which were predominantly 38 
HIV-1 Pol-specific. The animals showed a balanced polyfunctional CD4 and CD8 T-39 
cell response and high Ab titers.  40 
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Ideally a vaccine against human immunodeficiency virus type 1 (HIV-1) 47 
should be capable of inducing broadly neutralizing antibodies as well as effective T-48 
cell responses (Walker & Burton, 2008). Although these goals have not yet been 49 
achieved, results from the phase III Thai trial (RV144) indicate  that  with  a 50 
recombinant  canarypox  (ALVAC-HIV,  vCP1521)  prime  –  gp120  (AIDSVAX B/E) 51 
protein boost immunization strategy, that induces both CD4 T-cell as well as antibody 52 
responses,  the  risk  of  acquiring HIV-1  infection  is  decreased  (Haynes et al., 2012; 53 
Rerks-Ngarm et al., 2009).  54 
Three  of  the  best  characterized  highly  attenuated  pox  vectors  are  ALVAC, 55 
Modified Vaccinia virus Ankara (MVA) and NYVAC (Drexler et al., 2004; Franchini 56 
et al., 2004; Gomez et al., 2011; Paoletti et al., 1994). NYVAC was derived from the 57 
parental Copenhagen strain by deletion of 18 specific open reading frames, including 58 
the  host  range  genes  K1L  and  C7L.  Reinsertion  of  these  two  genes  resulted  in  an 59 
improved  vaccine  vector,  designated  NYVAC-KC,  which  yielded  higher  levels  of 60 
antigen  expression  in  infected  cells,  was  replication  competent  in  human 61 
keratinocytes  and  dermal  fibroblasts,  but  maintained  a  highly  attenuated  phenotype 62 
(Kibler et al., 2011). In addition, NYVAC-KC showed enhanced capacity to stimulate 63 
dendritic cell maturation, antigen processing and presentation and stimulation of CD8 64 
T-cell responses through cross presentation (Quakkelaar et al., 2011).  65 
Synthetic long peptides (SLP) are a relatively novel vaccine modality designed 66 
as approximately 30-mer peptides overlapping by 10 to 15 amino acids. The peptide 67 
length strongly favours processing by ‘professional’ antigen-presenting  cells  instead 68 
of  direct  binding  to major  histocompatibility  complex  class  I molecules  on  the  cell 69 
surface  and  this  provides  a  parallel  stimulation  of  both  CD4  T-helper  and  CD8 70 
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cytotoxic  T-cells (Melief & van der Burg, 2008; Zhang et al., 2009).  Using  this 71 
approach  for  human papilloma virus  16 we have  previously  demonstrated  a  clinical 72 
benefit  in  patients  with  high-risk  human  papilloma  virus  type  16-induced 73 
premalignant vulvar lesions (Kenter et al., 2009; Welters et al., 2010).  74 
  Both  broad  neutralizing  antibody  and  T-cell  inducing  vaccines  face  the 75 
problem  of  the  extreme  variability  of  the  HIV-1  genome.  To  address  HIV-1 76 
variability  and  escape,  a  novel  pan-clade  immunogen  HIVconsv  was  assembled, 77 
derived  from  the  14  most  conserved  regions  of  the  HIV-1  consensus  proteomes 78 
(Letourneau et al., 2007).  It  was  previously  demonstrated  that  immunization  with 79 
SLP,  covering  the  HIVconsv  sequence  greatly  enhanced  the  breadth  and  overall 80 
magnitude of the CD4 and CD8 T-cell response in DNA.HIVconsv/human adenovirus 81 
serotype  5  HAdV5.HIVconsv/  MVA.HIVconsv  immunized  animals,  but  was  less 82 
effective when used for priming (Rosario et al., 2012; Rosario et al., 2010). However, 83 
improved adjuvantation via simultaneous injection of pegylated type I IFN resulted in 84 
induction  of  high  immune  responses  after  two  immunizations  with  SLP.SIVconsv 85 
only (Koopman et al, 2013). In addition, increased expression of TRAIL on NK cells 86 
and  CD80  on  plasmacytoid  dendritic  cells  was  noted  2  days  following  SLP 87 
immunization  in  the  presence  of  type  I  IFN,  suggesting  enhanced  activation  of  the 88 
innate  immune system.  In contrast to the HIVconsv prime/boost strategies described 89 
by Rosario et al,  the type I IFN adjuvanted SLP was  found to induce predominantly 90 
CD4 T-cell  responses  of  central memory phenotype, while  only modest CD8 T-cell 91 
responses with limited breadth were generated (Koopman et al., 2013).  92 
Here, we explored the possibility of obtaining a more balanced CD4/CD8 T-93 
cell response by using a pox-vector prime/SLP boost strategy, employing the recently 94 
 5 
developed  replication  competent  NYVAC  vector  plus  type  I  IFN  adjuvanted 95 
SLP.HIVconsv.  96 
The  current  study  was  performed  in  six  mature  captive-bred  Indian  origin 97 
rhesus  monkeys  (R1-R6,  Macaca  mulatta),  housed  at  the  Biomedical  Primate 98 
Research Centre, Rijswijk, The Netherlands, according to international guidelines for 99 
non-human primate care and use (The European Council Directive 86/609/EEC, and 100 
Convention ETS 123, including the revised Appendix A). The animals were negative 101 
for  antibodies  to  SIV-1,  simian  type  D  retrovirus  and  simian  T-cell  lymphotropic 102 
virus.  During  the  course  of  the  study,  the  animals  were  checked  twice  daily  for 103 
appetite  and  general  behaviour  and  stools  were  checked  for  consistency.  At  each 104 
sedation  (ketamine  10mg/kg)  for  blood  collection or  immunization  the  body weight 105 
and  body  temperature  were  measured.  The  Institutional  Animals  Care  and  Use 106 
Committee (DEC-BPRC) approved the study protocols developed according to  strict 107 
international  ethical  and  scientific  standards  and  guidelines.  The  rhesus macaques 108 
were immunized at week 0, 4 and 12 by intradermal injection of NYVAC-C-KC-109 
Gag(ZM96)-Pol-Nef(CN54) (108 pfu per immunization). The generation of 110 
replication competent NYVAC-C-KC expressing the HIV-1 Clade C genes Gag (from 111 
isolate 96ZM651 (Acc.Nr. AF286224), abbreviated “ZM96”) and PolNef (from 112 
isolate 97CN54 (Acc.Nr. AX149647.1), abbreviated “CN54”), will be described 113 
elsewhere, and a similar vector expressing Gag-Pol-Nef from clade C CN54 was 114 
described previously (Kibler et al., 2011). The replication competent NYVAC vector 115 
containing  the  cassette  Gag  (ZM96)  and  Pol-Nef  (CN54)  produces  mainly  Gag  as 116 
VLPs  as  cell-released  products  and  to  a  lesser  extent  Pol-Nef  due  to  a  ribosomal 117 
frame-shift (Perdiguero et al., 2014).  The NYVAC vector was grown in primary CEF 118 
cells and purified by sedimentation through two 36% sucrose cushions. Virus titers 119 
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were determined by plaque assay in monkey BSC-40 cells. Subsequently, animals 120 
were boosted twice at week 58 and 62 with SLP.HIVconsv, given in a decreasing 121 
dose range of 100 and 30 μg of each peptide. SLP used in this study were based on 122 
the previously described HIVconsv sequence (Letourneau et al., 2007) and comprised 123 
a set of 33 peptides ranging in length from 26 to 27 amino acids (aa) and covering the 124 
Gag1,2,3, Pol 4,5,7,8,10 and Env 9,14  regions. Synthetic peptides were dissolved in 125 
20% dimethyl sulfoxide (DMSO), 20 mM PBS (pH 7.5) and divided into five sub-126 
pools; pp1 Gag1,2,3; pp2 Pol4; pp3 Pol5; pp4 Pol7,8,10; pp5 Env 9,14. On the day 127 
before vaccination, peptide pools were emulsified in Montanide ISA-720 (Seppic, 128 
Paris, France) adjuvant (DMSO/PBS/Montanide ISA-720 3:27:70, v/v/v) and kept at 129 
4 °C. Stability was checked as described before (Miles et al., 2005). Each of the 5 130 
vaccine peptide pools was injected s.c. at a separate site (right upper arm, left upper 131 
arm, right upper thigh, left upper thigh, lower back). Simultaneously, a dose of 132 
pegylated type I IFN (1 !g/kg) was given by s.c. injection. At the end of the 133 
procedure and again 48 hours later, the animals received on the injection sites topical 134 
imiquimod containing cream (Aldara Cream 5%, 12.5 mg imiquimod/250 mg cream) 135 
to enhance immunogenicity (Lore et al., 2003; Othoro et al., 2009). 136 
In  order  to  evaluate  the  immune  potency  of  the  prime  with  replication  competent 137 
NYVAC-C-KC (Quakkelaar et al., 2011), PBMC from six immunized animals were 138 
isolated using LSM density gradient centrifugation (Organon-Teknica) and tested for 139 
antigen-specific IFN" secretion by ELISPOT assay as described (Koopman et al., 140 
2008). As  shown  in  Fig.  1A,  clearly  detectable  antigen-specific IFNγ ELISpot 141 
responses  were  observed  already  after  one  immunization.  These  responses  were 142 
further  increased after  the  second  immunization  (p = 0.049,  t-test), but could  not be 143 
boosted anymore by a third NYVAC-C-KC immunization (p = 0.634, t-test) probably 144 
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because  of  the  induction  of  high  anti-vector  responses  (2850  ±  1740  spot  forming 145 
units  (SFU)  per  106  PBMC  (not  shown).  Responses  were  modest,  predominantly 146 
directed against gag (Fig. 1A), most probably because of a higher production of Gag 147 
VLPs  than  of  Pol-Nef,  due  to  the  nature  of  the NYVAC  vector  that makes  mainly 148 
extracellular  VLPs  (Perdiguero et al., 2014).  Responses  were  too  low  to  further 149 
characterize multifunctionality by ICS.   150 
At week 56, 44 weeks after the last NYVAC-C-KC immunization, memory T-151 
cell  responses  measured  against  HIV-1  Gag (ZM96, 2 pools),  the  most  dominant 152 
antigen after priming, were found to be negative in all animals (not shown). Likewise 153 
no IFNγ ELISpot responses were seen when animals were tested against the five 154 
conserved peptide pools  (Fig. 1B).  In contrast  to  the Gag dominated  responses  seen 155 
after priming,  the SLP booster  immunization  induced  besides  responses against Gag 156 
also  strong  responses  to  Pol  peptide  pools.  With  two  SLP  booster  immunizations, 157 
responses were amplified to above 2000 SFU/106 PBMC, but only  in  four out of six 158 
animals, the other two animals (R3 and R4) generating about 500 SFU/106 PBMC. In 159 
contrast,  previously  reported  SLP  booster  immunizations  in  DNA.HIVconsv/ 160 
HAdV5.HIVconsv/MVA.HIVconsv  primed  animals  or  DNA.SIVconsv  primed 161 
animals  gave  a  more  uniform  induction  of  high  responses  in  all  animals  over  time 162 
(Koopman et al., 2013; Raab et al., 2010).  Possibly,  the  application  of  different 163 
antigenic inserts, used for NYVAC priming and SLP booster immunization, may have 164 
contributed to less effective triggering of memory responses  in some animals  in this 165 
study, despite the considerable sequence overlap between the antigens (supplementary 166 
figure  1). Genetic  differences,  for  instance  in MHC  or KIR  expression  pattern  (not 167 
tested)  may  have  resulted  in  less  efficient  peptide  presentation  or  innate  immune 168 
stimulation  in  animals  R3  and  R4,  but  this  remains  speculative.  Importantly,  even 169 
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though  the  responses  against  Pol  were  very  low  after  priming,  the  SLP  booster 170 
immunization resulted in high Pol specific responses in three animals,  indicating that 171 
HIVconsv specific cross reactive memory responses can be triggered. Although Env 172 
was  only  included  during  boosting,  still  modest  responses  were  induced  in  two 173 
animals (Fig. 1B). The preferential amplification of Pol over Gag specific responses 174 
may be related to the composition of the SLP.HIVconsv immunogen, which contained 175 
7 Gag, 21 Pol and 5 Env peptides. 176 
Further  functional  characterization  of  vaccine-induced  cellular  immune 177 
responses for detection of IFN-γ, IL-2, and TNF-α (cytokine production, within CD4 178 
and CD8 T-cell subsets was performed by multiparameter flow cytometry (for FACS 179 
plot analysis, see supplementary figure 2) at the end of the study when animals were 180 
sacrificed  and  sufficient  PBMC  could  be  obtained  for  this  extensive  analysis,  as 181 
described  (Koopman et al., 2013). In the four animals with a high IFNγ ELISpot 182 
response  at  week  70,  strong  antigen-specific  CD4  and  CD8  T-cell  responses  were 183 
observed  (Fig.  2A).  Both CD4  and CD8 T-cell  responses were  polyfunctional with 184 
10-15%  triple  IFN-γ, IL-2,  TNF-α production  (Fig.    2B).  All  six  animals  were 185 
included  in this analysis. When comparing these results with IFNγ ELISpot and ICS 186 
responses induced by either SLP alone (SSS) and DNA prime and SLP boost (DDSS) 187 
described  before  (Koopman et al., 2013, supplementary figure 3),  it  becomes  clear 188 
that the magnitude and diversity of the IFNγ ELISpot responses as well as the antigen 189 
specific CD4 T-cell responses (ICS) were similar between the different immunization 190 
strategies  (supplementary  figure  3A  and  B,  left  and  middle  panels).  However, 191 
NYVAC  priming  followed  by  SLP  boosting  (NNNSS)  induced  higher  CD8  T-cell 192 
responses than DNA priming/SLP boosting (DDSS) (supplementary  figure 3A, right 193 
panel, p = 0.009, Mann-Whitney). More importantly, the diversity of the response was 194 
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highest  after NNNSS  immunization  (B,  right  panel, NNNSS versus SSS:  p =  0.009 195 
and NNNSS vs DDSS: p = 0.003, Mann-Whitney),  indicating that NYVAC priming 196 
followed by SLP boosting induced the most balanced CD4/CD8 T-cell response (both 197 
CD4 and CD8 T-cell responses with highest CD8 T-cell diversity). 198 
Antibody responses  to SLP.HIVconsv peptides measured by standard ELISA 199 
techniques (Koopman et al., 2013) were not induced by NYVAC-C-KC immunization 200 
(measured at 4 and 44 weeks post third immunization, not shown). Although it cannot 201 
be excluded that at these time points some antibody reactivity exists against the whole 202 
Gag  and Pol  proteins,  this  is  unlikely  as  these  responses  should  have  been  detected 203 
with  the SLP.HIVconsv peptides  due  to  the  considerable  sequence  overlap  between 204 
the  Gag  and  Pol  antigens  (supplementary  figure  1).  However,  all  SLP.HIVconsv 205 
boosted  animals  had  strong  antibody  responses  against  SLP.HIVconsv  peptides  (8 206 
weeks post 2nd boost, Fig. 3). 207 
The  increase  in  HIVconsv  specific  responses  in  animals  primed  with  a  divergent 208 
immunogen suggests that this strategy might also be useful for therapeutic vaccination 209 
in HIV-1  infected  people. However,  lack  of  pre-existing memory  responses  against 210 
the HIVconsv immunogen might be an issue, resulting in either poor enhancement or 211 
induction of  responses with  limited  breadth, a phenomenon also observed  in  two of 212 
our  SLP  boosted  animals.  This  NYVAC-C-KC  prime/SLP.HIVconsv  booster 213 
vaccination strategy demonstrated proof-of-concept  induction of  balanced CD4/CD8 214 
T-cell  responses  and  antibody  responses,  albeit  not  in  all  animals  immunized. 215 
Potentially,  this  strategy  could  increase  the  level  of  protection  against  intrarectal 216 
SIVmac251  challenge  that  was  obtained  in  a  SIVconsv  DNA  prime/SLP  boost 217 
strategy  (Koopman et al., 2013).  Unfortunately,  this  could  not  be  tested  in  this 218 
particular study because of the HIV origin of the immunogens. 219 
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Figure legends 336 
 337 
Fig.  1.  IFNγ ELISpot responses. (a) Antigen specific responses during NYVAC-C-338 
KC  priming  (week  0-14),  against  clade  C  peptide  pools.  (b)  Antigen  specific 339 
responses  during  SLP.HIVconsv  boosting  (week  56-70),  against  five  conserved 340 
peptide pools. Please note the difference in scales used for the Y-axis. 341 
 342 
Fig.  2.  Antigen  specific  cytokine  responses  measured  by  ICS.  (a)  Magnitude  of 343 
combined IFNγ, IL-2, TNFα cytokine response measured after the second 344 
SLP.HIVconsv  booster  immunization  (week  70).  Expressed  is  the  percentage  of 345 
positive  CD4  and  CD8  T-cells,  specified  for  each  of  the  five  peptide  pools.    (b) 346 
Cytokine expression pattern of total antigen specific response (mean responses of all 5 347 
peptide pools combined of all six animals) in CD4 and CD8 T-cells. Pies indicate the 348 
relative number of cells expressing one (dark), two (dark grey) or three (light grey) 349 
cytokines. Arcs indicate production of IFN-"# IL-2 and TNF-$.  350 
 351 
Fig. 3. Antibody responses. Antibody responses in serum against the HIVconsv long 352 
peptides, measured at week 70. Shown  is dilution  titre of positive  response. Lowest 353 
dilution tested =1:100. 354 
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